New Investigational Oral Therapy, Afimetoran, for Systemic Lupus Erythematosus Meets Phase 2 Trial Endpoint

A new investigative therapy, afimetoran, for adults with systemic lupus erythematosus (SLE) met its primary endpoint in a Phase 2 global, double-blind, randomized, dose-ranging, placebo-controlled trial (NCT04895696), showing a clear, statistically significant, and clinically meaningful benefit.

This post was originally published on this site